Cart is empty British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a common form of liver disease, in a deal worth up to $2 billion.
British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a common form of liver disease, in a deal worth up to $2 billion.
Leave A Comment